Skip to content

Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, bought INBX on Sep 25, 2026

Data as of Oct 16

▲ BUY$217K2,176 shares at $99.60Mark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.
Watch INBX
Traded
Sep 25, 2026
Disclosed
Sep 28, 2026
Filed
3 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, bought INBX on Sep 25, 2026TRADEDDISCLOSED
INBXSimilar stocks (XLV — its sector index fund), rebased to INBX's price on the disclosure day
INBX since disclosure
−11.7%
Similar stocks (XLV) since disclosure
+3.2%
XLV — its sector index fund

Change in closing price from Sep 28, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$305Kdisclosed Sep 28 · filed the same day
  2. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$148Kdisclosed Sep 28 · filed the same day
  3. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$329Kdisclosed Sep 28 · filed 3 days after the trade

See every trade on INBX →